[go: up one dir, main page]

WO2004097009A3 - METHOD TO IDENTIFY AGENTS THAT ACTIVATE OR INHIBIT IKKi - Google Patents

METHOD TO IDENTIFY AGENTS THAT ACTIVATE OR INHIBIT IKKi Download PDF

Info

Publication number
WO2004097009A3
WO2004097009A3 PCT/EP2004/004604 EP2004004604W WO2004097009A3 WO 2004097009 A3 WO2004097009 A3 WO 2004097009A3 EP 2004004604 W EP2004004604 W EP 2004004604W WO 2004097009 A3 WO2004097009 A3 WO 2004097009A3
Authority
WO
WIPO (PCT)
Prior art keywords
ikki
inhibit
activate
identify agents
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/004604
Other languages
French (fr)
Other versions
WO2004097009A2 (en
Inventor
Vladimir Kravchenko
Frank Mercurio
Richard J Ulevitch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Scripps Research Institute
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG, Scripps Research Institute filed Critical Novartis Pharma GmbH Austria
Publication of WO2004097009A2 publication Critical patent/WO2004097009A2/en
Publication of WO2004097009A3 publication Critical patent/WO2004097009A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides methods for the use of agents that increase or decrease the expression or activity of IKKi to regulate cellular processes, such as inflammation, cellular differentiation, cellular proliferation, tissue regeneration, neurodegeneration and complement activation. In addition, the invention provides a method to identify agents that increase or decrease the expression or activity of IKKi.
PCT/EP2004/004604 2003-05-01 2004-04-30 METHOD TO IDENTIFY AGENTS THAT ACTIVATE OR INHIBIT IKKi Ceased WO2004097009A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46766503P 2003-05-01 2003-05-01
US60/467,665 2003-05-01

Publications (2)

Publication Number Publication Date
WO2004097009A2 WO2004097009A2 (en) 2004-11-11
WO2004097009A3 true WO2004097009A3 (en) 2005-02-17

Family

ID=33418453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/004604 Ceased WO2004097009A2 (en) 2003-05-01 2004-04-30 METHOD TO IDENTIFY AGENTS THAT ACTIVATE OR INHIBIT IKKi

Country Status (1)

Country Link
WO (1) WO2004097009A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034978A2 (en) * 2003-10-02 2005-04-21 Xantos Biomedicine Ag MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF
EP2259787B1 (en) 2008-03-25 2015-12-23 The Regents of the University of Michigan Ikki inhibitor therapies and screening methods, and related ikki diagnostics
EP2675275B1 (en) 2011-02-14 2017-12-20 The Regents Of The University Of Michigan Compositions and methods for the treatment of obesity and related disorders
US9365581B2 (en) 2013-05-02 2016-06-14 The Regents Of The University Of Michigan Deuterated amlexanox
US10370664B2 (en) 2013-11-07 2019-08-06 University Of Southern California Use of IKK epsilon inhibitors to activate NFAT and T cell response
US10435375B2 (en) 2015-05-05 2019-10-08 Northwestern University CXCR4 chemokine receptor modulators
US9987242B2 (en) 2015-05-05 2018-06-05 Northwestern University Treatment of Levodopa-induced Dyskinesias
WO2017132538A1 (en) 2016-01-29 2017-08-03 The Regents Of The University Of Michigan Amlexanox analogs
WO2018013951A1 (en) 2016-07-15 2018-01-18 Northwestern University Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias
US11554103B2 (en) 2016-11-10 2023-01-17 Northwestern University Compositions and methods to reduce pharmaceutical-induced toxicity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039308A1 (en) * 1998-12-24 2000-07-06 Glaxo Wellcome Kabushiki Kaisha Ikk3 kinase
EP1043397A1 (en) * 1998-10-26 2000-10-11 Japan Science and Technology Corporation IDENTIFICATION OF NOVEL SUBSTRATE I-TRAF OF IKK-i KINASE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043397A1 (en) * 1998-10-26 2000-10-11 Japan Science and Technology Corporation IDENTIFICATION OF NOVEL SUBSTRATE I-TRAF OF IKK-i KINASE
WO2000039308A1 (en) * 1998-12-24 2000-07-06 Glaxo Wellcome Kabushiki Kaisha Ikk3 kinase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FITZGERALD KATHERINE A ET AL: "IKKepsilon and TBKI are essential components of the IRF3 signaling pathway.", NATURE IMMUNOLOGY, vol. 4, no. 5, May 2003 (2003-05-01), pages 491 - 496, XP002297126, ISSN: 1529-2908 *
KRAVCHENKO VLADIMIR V ET AL: "IKKi/IKKepsilon plays a key role in integrating signals induced by pro-inflammatory stimuli.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 29, 18 July 2003 (2003-07-18), pages 26612 - 26619, XP002297127, ISSN: 0021-9258 *
PETERS^1 R T ET AL: "A new family of IKK-related kinases may function as IkappaB kinase kinases", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1471, no. 2, 26 January 2001 (2001-01-26), pages M57 - M62, XP004248862, ISSN: 0304-419X *

Also Published As

Publication number Publication date
WO2004097009A2 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
WO2004018058A3 (en) Compounds, compositions, and methods
WO2006023649A3 (en) Treatment of severe multiple sclerosis
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
AU2005302085A1 (en) Copper containing materials for treating wounds, burns and other skin conditions
WO2007140002A3 (en) Method for treating non-hodgkin's lymphoma
WO2007014278A3 (en) B-cell reduction using cd37-specific and cd20-specific binding molecules
MY140767A (en) Compounds, methods and compositions
WO2006113432A3 (en) Compounds, compositions and methods
WO2004080430A3 (en) Methods of improving skin quality
WO2005113590A3 (en) Bmp10 propeptides and related methods
WO2004058700A3 (en) Mitotic kinesin inhibitors
WO2004058148A3 (en) Mitotic kinesin inhibitors
WO2003088903A3 (en) Compounds, compositions, and methods
WO2005007141A3 (en) Ubiquitin ligase inhibitors and methods related thereto
WO2004006853A3 (en) Treatment and prophylaxis with 4-1bb-binding agents
WO2005065269A3 (en) Compositions and method for decreasing the appearance of skin wrinkles
WO2004009036A3 (en) Compounds compositions and methods
WO2004034972A3 (en) Compounds, compositions, and methods
WO2004064741A3 (en) Compounds, compositions, and methods
WO2004097009A3 (en) METHOD TO IDENTIFY AGENTS THAT ACTIVATE OR INHIBIT IKKi
WO2006055871A3 (en) Treatment for multiple sclerosis
WO2004006865A3 (en) Compounds, compositions, and methods
WO2006039691A3 (en) Morphine and morphine precursors
WO2004032840A3 (en) Compounds, compositions, and methods
WO2006069253A3 (en) Trefoil factors and methods of treating proliferation disorders using same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase